<!DOCTYPE html>
<html>
<meta charset="UTF-8">
<head>
    <title>HLA-A——ERBB2 - PMID Details</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            line-height: 1.6;
            color: #333;
        }

        h1 {
            text-align: center;
            font-size: 2.5em;
            color: #2c3e50;
            margin-bottom: 20px;
        }

        /* Navbar Styles */
        nav {
            background-color: #2c3e50;
            padding: 10px 20px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            color: white;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        nav .navbar-left, nav .navbar-right {
            display: flex;
            align-items: center;
        }

        nav a {
            color: white;
            text-decoration: none;
            margin: 0 15px;
            font-size: 1.1em;
            transition: color 0.3s ease;
        }

        nav a:hover {
            color: #f39c12;
        }

        nav .divider {
            color: #ecf0f1;
            margin: 0 10px;
        }

        /* Page Footer */
        footer {
            margin-top: 40px;
            padding: 10px 20px;
            background-color: #f7f7f7;
            color: #333;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        /* Tab and Content Styles */
        .tab {
            display: flex;
            flex-wrap: wrap;
            justify-content: center;
            margin-bottom: 20px;
        }

        .tab button {
            padding: 10px 20px;
            margin: 5px;
            margin-bottom: 10px;
            cursor: pointer;
            background-color: #f4f4f4;
            border: 2px solid #ddd;
            border-radius: 5px;
            font-size: 1.1em;
            transition: background-color 0.3s ease;
            flex-basis: calc(10% - 10px);
            box-sizing: border-box;
        }

        .tab button:hover {
            background-color: #ecf0f1;
        }

        .tab button.active {
            background-color: #3498db;
            color: white;
            border-color: #2980b9;
        }

        .tabcontent {
            display: none;
            padding: 20px;
            margin-top: 10px;
            background-color: #ecf0f1;
            border-radius: 5px;
            box-shadow: 0px 0px 10px rgba(0, 0, 0, 0.1);
        }

        .tabcontent.active {
            display: block;
        }

        .tabcontent h2 {
            font-size: 2em;
            color: #2980b9;
        }

        .tabcontent p {
            font-size: 1.2em;
            line-height: 1.8;
        }

        /* Emphasize Title and Abstract */
        .title, .abstract {
            background-color: #f9f9f9;
            padding: 20px;
            margin: 10px 0;
            border-left: 5px solid #2980b9;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
        }

        .abstract {
            border-left: 5px solid #e74c3c;
        }
    </style>
    <script>
        function adjustTabStyle() {
            var tabCount = document.querySelectorAll('.tab button').length;
            var tabContainer = document.querySelector('.tab');

            if (tabCount > 10) {
                tabContainer.classList.add('small-tabs');
            }
        }

        function openTab(evt, tabId) {
            document.querySelectorAll(".tabcontent").forEach(tab => tab.style.display = "none");
            document.querySelectorAll(".tablinks").forEach(link => link.classList.remove("active"));
            document.getElementById(tabId).style.display = "block";
            evt.currentTarget.classList.add("active");
        }

        window.onload = adjustTabStyle;
    </script>
</head>
<body>
    <nav>
        <div class="navbar-left">
            <a href="">ConnectomeDB</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/">Home</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/database.html">Database</a>
        </div>
        <div class="navbar-right">
            <a href="https://www-user.yokohama-cu.ac.jp/~bioinfo/">YCU Bioinformatics Lab</a>
            <span class="divider">|</span>
            <a href="https://perkins.org.au/research/labs/cancer-program/systems-biology-and-genomics-overview/">Perkins Systems Biology & Genomics Lab</a>
        </div>
    </nav>

    <h1>PMID Details for HLA-A——ERBB2</h1>

    <div class="tab">
        <button class="tablinks active" onclick="openTab(event, 'tab10593938')">10593938</button>
    </div>

    <div class="tabcontent" id="titleTab">
        <div class="title">
            <h2>Title</h2>
            <p>{{TITLE}}</p>
            <i> Journal:{{JOURNAL}}; Year Published:{{YEAR}}</i>   
        </div>
    </div>

    <div class="tabcontent" id="abstractTab">
        <div class="abstract">
            <h2>Abstract</h2>
            <p>{{ABSTRACT}}</p>
        </div>
    </div>

    
                <div id="tab10593938" class="tabcontent active">
                    <h2>Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide.</h2>
                    <h3>The Journal of biological chemistry; 1999</h3>
                    <p>Class I major histocompatibility complex (MHC) molecules bind short peptides derived from proteins synthesized within the cell. These complexes of peptide and class I MHC (pMHC) are transported from the endoplasmic reticulum to the cell surface. If a clonotypic T cell receptor expressed on a circulating T cell binds to the pMHC complex, the cell presenting the pMHC is killed. In this manner, some tumor cells expressing aberrant proteins are recognized and removed by the immune system. However, not all tumors are recognized efficiently. One reason hypothesized for poor T cell recognition of tumor-associated peptides is poor binding of those peptides to class I MHC molecules. Many peptides, derived from the proto-oncogene HER-2/neu have been shown to be recognized by cytotoxic T cells derived from HLA-A2(+) patients with breast cancer and other adenocarcinomas. Seven of these peptides were found to bind with intermediate to poor affinity. In particular, GP2 (HER-2/neu residues 654-662) binds very poorly even though it is predicted to bind well based upon the presence of the correct HLA-A2.1 peptide-binding motif. Altering the anchor residues to those most favored by HLA-A2.1 did not significantly improve binding affinity. The crystallographic structure shows that unlike other class I-peptide structures, the center of the peptide does not assume one specific conformation and does not make stabilizing contacts with the peptide-binding cleft.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/10593938/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                

    <footer>
        <span>© Copyright 2024, YCU Bioinformatics Laboratory</span>
        <span>Page built with <a href="https://quarto.org/">Quarto</a> by バイオインフォマティクス解析センター</span>
    </footer>
</body>
</html>
